Antibody targeted thrombin-activatable ?-plasminogen fusion proteins and nanocapsules for the treatment of acute thrombosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1028145

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The clinical consequences of atherosclerosis such as myocardial infarction and stroke are the major cause of mortality and morbidity in Australia. Clot dissolving agents have been proven to be beneficial in patients with acute myocardial infarction, vein thrombosis, pulmonary embolism, and stroke. However, the currently available drugs have major limitations in efficacy and in safety. The aim of this project is to develop novel drugs that have the potential to improve both significantly.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $536,951.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Biotechnology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody therapy | drug delivery systems | myocardial infarction | nanotechnology | plasminogen | platelets | stroke | targeted therapy | thrombolysis | thrombosis

Related Links